RemeGen Co., Ltd. (09995) climbed more than 6% in early trading, with the stock up 5.92% as of press time at HK$66.25, on turnover of HK$128.3 million.
On November 2, RemeGen announced that its board of directors had approved a proposal for a second share buyback in 2026 via centralized competitive bidding, under which the company plans to use its own funds and/or self-raised funds to repurchase its A shares through centralized competitive bidding.
The repurchased shares will be used to safeguard the company's value and shareholders' interests. The buyback amount will be no less than RMB 30 million (inclusive) and no more than RMB 60 million (inclusive), with the repurchase price not exceeding RMB 131 per share (inclusive).
In addition, RemeGen announced that, as of October 31, 2026, the company had cumulatively repurchased 60,000 shares through the Shanghai Stock Exchange trading system via centralized competitive bidding, representing 0.0106% of the company's total share capital. The highest repurchase price was RMB 113.7 per share and the lowest was RMB 108.30 per share, with total funds paid amounting to RMB 6.632 million (excluding trading commissions and other transaction fees).
Comments